Company: RPTX
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030405
Chunk: 95

Company: Repare Therapeutics Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 95
---
        $
        (36
        )
         
        $
        112,359

      Interest receivable was $0.4 million and $0.4 million as of December 31, 2024 and 2023, respectively, and is included in other current receivables.The Company held available-for-sale marketable securities with an aggregate fair value of $7.8 million and $58.6 million that were in an unrealized loss position as of December 31, 2024 and 2023, respectively. These marketable securities have been in an unrealized loss position for less than twelve months. The unrealized losses as of December 31, 2024 were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. The Company does not intend to sell these securities and it is more likely than not that it will hold these investments for a period of time sufficient to recover the amortized cost. As a result, the Company did not record an allowance for credit losses or other impairment charges for its marketable securities for the year ended December 31, 2024.The Company recognized nil and $0.5 million net unrealized gain in other comprehensive income for the years ended December 31, 2024 and 2023, respectively.The maturities of the Company’s marketable securities as of December 31, 2024 and 2023 are less than one year.

115

4. Fair Value Measurements The following table presents information about the Company’s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values: 

        Description
         
        Financial Assets

        Level 1

        Level 2

        Level 3

        (in thousands)

        As at December 31, 2024

         Assets

         Cash equivalents:

         Money market funds
         
        $
        25,522

        $
        25,522

        $
        —

        $
        —

         Commercial paper

        15,433

        —

        15,433

        —

         Total cash equivalents

        40,955

        25,522

        15,433

        —

         Marketable securities:

         U.S. Treasury and government-sponsored enterprises

        3,014

        —

        3,014

        —

         Commercial paper

        40,726

        —